ArticleMethods in molecular biology (Clifton, N.J.)2025
In Vitro Model to Test Therapeutic Agents Against Rhinovirus Infection.
Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To develop an antiviral drug, it is extremely important to have a relevant cell culture model system. The airway epithelial cells lining the conductive airways are the primary target for all three classes of rhinoviruses. However, rhinovirus replication is not very robust in airway epithelial cells; therefore, it does not cause cytopathic effects. However, rhinovirus induces replication-dependent cytokines such as type I and type III interferons and CXCL-10, which can be used as surrogates for viral load. Here, we describe a method using the immortalized normal human bronchial epithelial cell line, BEAS-2B cells. These cells readily grow in serum-free medium and can be infected with rhinovirus A and B. The binding, endocytosis, and replication of the virus induce CXCL-8 in these cells. These cells also respond to replicating virus by showing robust CXCL-10 production. Both CXCL-8 and CXCL-10 secreted into the medium can be readily measured by ELISA. Therefore, this method can be used to examine the drugs that can inhibit binding, endocytosis, and replication of the virus.
Indexed as
Identifiers
40016467What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.